Frontlight ResearchEarly access
Taking people in United StatesNo phase
Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)
Key facts
- Who runs it
- Midwest Veterans' Biomedical Research Foundation
- Where
- Kansas City, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 36 people, planned
- Started
- 15 Feb 2022
- Expected to end
- 1 Apr 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ARAT
- Sham intervention (control)
- Record updated
- 27 February 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- Chronic GERD symptoms (at least 1 typical symptom of GERD, i.e. heartburn or acid reflux/regurgitation at least twice a week) for last 6 months
- Objective evidence of reflux disease (positive ambulatory pH study.)
Who cannot take part
- Esophageal stricture with any prior intervention
- Previous fundoplication, myotomy or LINX surgery
- Allergic or intolerant to PPI medications
- Major motility disorder
- Age <18 years or >80 years
- Patients unable to or unwilling to participate or consent
- Large hiatal hernia > 3 cm and Hill grade IV
- Barrett's esophagus
- Eosinophilic esophagitis
- Gastroparesis documented by abnormal gastric emptying time
- Cirrhosis with esophageal and/or gastric varices
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Gastro esophageal reflux
This trial is currently available in United States.
- Kansas City VA HospitalKansas City, United StatesContact: April Higbee, BSNTaking people
About the trial
What the trial wants to find out
This will be a randomized clinical trial examining the efficacy and safety of ARAT (intervention group) in patients with chronic GERD symptoms (typical symptoms of GERD, i.e. heartburn or acid reflux/regurgitation at least twice a week) for the last 6 months.
Read full original descriptionShow less
Patients must have a positive pH test and a negative manometry (no treatment) procedure.
The 2 groups in the trial
- Anti-reflux mucosal ablation (ARAT)Existing treatment, for comparison
ablation in the gastric cardia using hybrid argon plasma coagulation
Treatment: ARAT
- No treatmentSham treatment, for comparison
no ablation
Treatment: Sham intervention (control)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation (AREA) in Gastroesophageal Reflux Disease (GERD) Patients: A Single Center, Randomized, Sham, Controlled Trial (The AREA Study)
- Criteria questions
- Built from NCT05570448, who can take part
- Record updated
- 27 February 2026